Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Yeah, so the EGFR mutation lung cancer ...
Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with advanced relapsed/refractory solid tumors, lymphoma, or ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する